Feishang Anthracite Resources Ltd

Industry: Mining

Main business locations: China, Hong Kong 

Registered office:
Maples Corporate Services (BVI) Limited
Kingston Chambers, P.O. Box 173
Road Town, Tortola
British Virgin Islands

Incorporation year: 2010

Legal advisers:
MinterEllison LLP - Hong Kong
Commerce & Finance Law Offices - PRC
Maples and Calder - BVI

About the BVI company:

Feishang Anthracite Resources Ltd is a BVI-domiciled company with headquarters and main place of business in Hong Kong. The group is engaged in the acquisition, development and construction of anthracite coal mines and extraction and sale of anthracite coal in China. It operates in one business unit based on its products and has only one reportable segment, with seven underground anthracite coal mines based in Guizhou province of the PRC, of which five have started commercial production, one is undergoing its pilot run phase and one is under construction. As of July 31, 2013, the company had total coal reserves of approximately 208.87 million tonnes and total permitted annual production capacity of 2.34 million tonnes.

Feishang Anthracite Resources was incorporated as a wholly-owned subsidiary of CHNR, a BVI company listed on the NASDAQ Capital Market.

Biohaven Pharmaceutical Holding Company Ltd.

Industry: Biopharmacy, Future technologies

Main business locations: Worldwide

Registered office:
C/O Maples Corporate Services (BVI) Limited
Kingston Chambers, Sea Meadow House
Road Town, Tortola
British Virgin Islands

Listed on: NYSE

About the BVI company:

Biohaven Pharmaceutical Holding is a company registered in the British Virgin Islands and listed on the New York Stock Exchange, focused on finding treatments for neurological diseases. It is a clinical-stage company with portfolio comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases.

Biohaven combines internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven had its first public offering in 2017. The company has multiple clinical trials across product candidates.